ReviewPsychology research and behavior management2025
Clinical Utility of Long-Acting Injectable Risperidone in Schizophrenia and Bipolar I Disorder: A Review of Clinical Studies.
Review in Psychology research and behavior management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Risperidone long-acting in-situ microimplant following a brief oral risperidone lead-in in the acute inpatient management of manic episodes with psychotic symptoms in non-adherent patients with schizoaffective disorder: a retrospective, uncontrolled real-world study.Annals of general psychiatry · 2026Article
- Efficacy and Safety of Risperidone Microspheres for Injection (II) in Patients With Schizophrenia Spectrum Disorders: A Prospective, Single-Arm, Multicenter Real-World Study.Alpha psychiatry · 2026Article
- Clinical Consequences of Inadvertent Intramuscular Administration of Subcutaneous Risperidone Formulation.Case reports in psychiatry · 2026Article
- Impact of treatment with long‑acting injectable antipsychotics on hospitalization and relapse rates in schizophrenia spectrum disorders: a 3‑year follow-up mirror‑image study.Therapeutic advances in psychopharmacology · 2026Article
- Clinical Benefit and Risk Profile of TV-46000 for Patients with Schizophrenia as Assessed by Number Needed to Treat and Number Needed to Harm.Neuropsychiatric disease and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risperidone was the first second-generation antipsychotic to be developed as a long-acting injectable (LAI). In the early 2000s, a risperidone microsphere formulation, intramuscularly administered every 2 weeks (BW-RLAI), was introduced. To date, five different risperidone LAI formulations have been marketed - including a second biweekly microsphere injection (LY03004), a newer monthly intramuscular formulation using in situ microparticles (ISM) technology that does not require an oral risperidone run-in, and two subcutaneous formulations (RBP-7000 and TV-46000). Understanding the advantages and limitations of each option is essential for tailoring treatment regimens based on clinical needs and patient preferences. In this review, with the aim of offering insights for clinical practice and future research, we provide a comprehensive synthesis of the currently available risperidone LAI formulations, examining their efficacy and safety for the treatment of schizophrenia and bipolar I disorder. While evidence supporting the efficacy, tolerability, and safety of risperidone LAI for schizophrenia is available for all marketed formulations to date, advantages for newer formulations, such as longer dosing intervals without oral supplementation, are also reviewed. In addition, although the Food and Drug Administration approved the biweekly LAIs for bipolar I disorder, there is no data on effectiveness of the other risperidone LAI formulations for this indication so far. The variety of the available risperidone LAI options is likely to enable a more personalized treatment approach. To facilitate this, healthcare providers should develop a comprehensive understanding of these formulations to select the most suitable option. While risperidone ISM, RBP-7000, and TV-46000 may enhance treatment feasibility and adherence, further research is needed to build an evidence base comparable to that available for BW-RLAI, particularly in the treatment of BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.